Experiencia con ibuprofeno para el tratamiento de la persistencia de conducto arterioso en un hospital de tercer nivel en la Ciudad de México

Cordero-González, Guadalupe; Gómez-Tamayo, T.; Santillán-Briceño, V.; Machuca-Vaca, A.; Fernández-Carrocera, Luis Alberto

doi:10.1016/j.rprh.2016.11.007

Cited by 2 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDA has a high frequency in the Mexican population, especially in preterm infants [3]. At birth, hemodynamically significant PDA is treated with COX inhibitors, and oral ibuprofen is the treatment of choice at the National Institute of Perinatology, but the use of these types of drugs generates adverse effects that can further complicate patient health.…”

Section: Discussionmentioning

confidence: 99%

“…In the National Institute of Perinatology, the most commonly used pharmacological treatment is ibuprofen. In the aforementioned study at the National Institute of Perinatology, 47.7% success was found with 10 mg/kg/d ibuprofen on the first day followed by 5 mg/kg/d ibuprofen on the second and third days, respectively, and 42.8% success was observed during the second cycle [3].…”

Section: Introductionmentioning

confidence: 93%

“…Oral ibuprofen treatment was used as follows: the first cycle of 10 mg/kg/d on the first day, followed by 5 mg/kg/d on the second and third days, respectively. In the case that no clinical and echocardiographic response was obtained (Supplementary Materials), a second oral ibuprofen cycle was administered (20 mg/kg/d), followed by a second and third dose at 10 mg/kg/dose, with administration intervals of 24 h between the doses [3]. The sample population was separated into two groups.…”

Section: Study Populationmentioning

confidence: 99%

“…The National Institute of Perinatology is a tertiary-level hospital, where 300 preterm newborns weighing <1500 g are born each year. An observational study performed in 2016 in 295 preterm infants between 27 and 28 weeks found PDA in 21.6% of patients [3]. The diagnostic gold standard is two-dimensional color Doppler echocardiography, which can determine the shape and diameter of the ductus arteriosus at the aortic and pulmonary edges and the degree of hemodynamic burden [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association of the EPAS1 rs7557402 Polymorphism with Hemodynamically Significant Patent Ductus Arteriosus Closure Failure in Premature Newborns under Pharmacological Treatment with Ibuprofen

Rogel-Ayala,

Muñoz-Medina,

Vicente-Juárez

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Patent ductus arteriosus (PDA) is frequent in preterm newborns, and its incidence is inversely associated with the degree of prematurity. The first choice of pharmacological treatment is ibuprofen. Several genes, including EPAS1, have been proposed as probable markers associated with a genetic predisposition for the development of PDA in preterm infants. EPAS 1 NG_016000.1:g.84131C>G or rs7557402 has been reported to be probably benign and associated with familial erythrocytosis by the Illumina Clinical Services Laboratory. Other variants of EPAS1 have been previously reported to be benign for familial erythrocytosis because they decrease gene function and are positive for familial erythrocytosis because the overexpression of EPAS1 is a key factor in uncontrolled erythrocyte proliferation. However, this could be inconvenient for ductal closure, since for this process to occur, cell proliferation, migration, and differentiation should take place, and a decrease in EPAS1 gene activity would negatively affect these processes. Single-nucleotide polymorphisms (SNPs) in EPAS1 and TFAP2B genes were searched with high-resolution melting and Sanger sequencing in blood samples of preterm infants with hemodynamically significant PDA treated with ibuprofen at the National Institute of Perinatology. The variant rs7557402, present in the EPAS1 gene eighth intron, was associated with a decreased response to treatment (p = 0.007, OR = 3.53). The SNP rs7557402 was associated with an increased risk of pharmacological treatment failure. A probable mechanism involved could be the decreased activity of the product of the EPAS1 gene.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

Section: Study Populationmentioning

confidence: 99%